{
  "doc_id": "Θεραπευτικά_Πρωτόκολλα_ΕΟΠΕ-10η_Έκδοση",
  "created_date": "2024",
  "country": "EL",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "3SY. KNATHRINSHOUSE... (OF. OF...) CONTINUED...SPECIFIC. SPECIFIC... ... B4.. NATION. NATION.THE...B5.",
      "start_page": 3,
      "end_page": 9
    },
    {
      "heading": "added, added,",
      "text": "its its hyperthetical-CPRI_HER CPRI_HER (Hyperthetic-resonant) therapy therapy (Blumps-HER hypothesized hyperthesis) (app) molar molar 1k:",
      "start_page": 10,
      "end_page": 12
    },
    {
      "heading": "or or EC",
      "text": "Doxorubicin 60 mg/75-90 75-90 mg/ 600 600 mg/M 2, IV",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2. TC",
      "text": "Docetaxel 75 mg/600 600 mg/ m2, I V",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "EC EC + Taxane",
      "text": "Doxorubicin 60 mg/75-90 75-90 mg/ 600 600 mg/80 80 mg/7 7 15:- 1a00 mepeg/134. 134.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "4. FEC",
      "text": "5-FU 500 mg/75-100 75-100 mg/ Cyclophosphamide Cyclophosphamide 500mg/Csametheus Csametheus i2h1d: cycles cycles suggests",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "5. FEC + Taxane",
      "text": "5-FU 500 mg/75-100 75-100 mg/ Cyclophosphamide Cyclophosphamide 500mg/m m g/175 175 mg/M2 IV; or or Dmoeciotaxe:l t7o5 σ-1x0h0",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "6. TAC",
      "text": "Docetaxel 75 mg/50 50 mg/500 500 mg/ Csamethe Csamethe i2h1w: xhaGa-Cna. xhaGa-Cna.",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "Cyclophosphamide 100mg/1 1 -14, PO",
      "text": "Methotrexate 40 mg/5-FU 5-FU 600mg/8, 8, IV",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "8. CMF (intravenous)",
      "text": "Cyclophosphamide 600mg/m2, d1+40 40 mg/m2 , d1+600 600 mg/ m2, d1-1-8",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "9. TCH (patients with HER2+ volume)",
      "text": "IV_Dacetaxel 75 mg/6 6 mg/kg, IV (8 8 mg/ kg) TCHP TCHP (comple with HER2+ volume) Docetaxel75 mg/ m2, IV",
      "start_page": 14,
      "end_page": 15
    },
    {
      "heading": "12. Paclitaxel + Trastuzumab",
      "text": "Paclitaxel 80 mg/2 2 mg/kg, IV (4 4 mg/ kg) 12-cycles 12-cycles Asymcomeleose: 6 6 epigl/a. a.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "13. Neratinib",
      "text": "Sneermaetiosisb 2:with with HER2+ __MEDterm1__. __MEDterm1__.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "and and Chemotherapy",
      "text": "__MEDTERM0_: weeks weeks (6 6 weeks). weeks weeks (5 5 doses)",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "15. Olaparib",
      "text": "mg mg (combination combination dose) every 3 weeks",
      "start_page": 16,
      "end_page": 16
    },
    {
      "heading": "A1. EPOCURATE ORMONOTHERAPY",
      "text": "tamoxifen tamoxifen (tamoxifen) 20 mg/risk risk (per per day) the following factor(s) daily daily (1 1 μg/day) months months (insteading) double double anti- HER2 therapy (_MEDM3).",
      "start_page": 16,
      "end_page": 19
    },
    {
      "heading": "B. STATISTICAL DISEASE",
      "text": "overexpression/HER2 HER2 (c-erbB-2) treatment treatment (if anthracycline and/and and if",
      "start_page": 19,
      "end_page": 19
    },
    {
      "heading": "B1. HARMONIOUS DISEASE",
      "text": "kinases kinases 4/6 [CDK4/6 recombined (_MEDTERM0_,_MEDDERM1_, __MEDERM2_) 5 5 mg/day; anastrozole (anastrozole) of of 1mg/exemestane exemestane (exemestan) dose.",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Tamoxifen. (tamoxifen) 20 mg/day",
      "text": "inhibitors inhibitors 4/6 [CDK4/6 (_MEDTERM0_, __MEDTERm1_,_MEDterm2_rol)] postmenopausal postmenopausal HR+/ HER2- non-3. non-3.",
      "start_page": 20,
      "end_page": 21
    },
    {
      "heading": "Epirubicin 75-100 mg/doxorubicin doxorubicin 60-75mg/m2; 21 21 days",
      "text": "Doxorubicin Doxorubicin 20mg/weekly. weekly.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "25-30 25-30 mg/60-80 60-80 mg/ 8 8 , every 21 days",
      "text": "doxorubicin doxorubicin (Caelyx) 50 mg/doxorubicin doxorubicin (Myocet) 60-75 mg/paclitaxel paclitaxel (Abraxane) 260 mg/ in in 30’ infusion",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "12. Gemcitabine 800-1200mg/21 21 days",
      "text": "IHC IHC 1+ or 2+/after after pr",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "mg/21 21 days",
      "text": "with with cdK4/least least : 10mg/10 10 mg/days, days, IV+ Paclitaxel 90 mg/of of >capechtabine capechtabine patients' anthracyclines anthracyclines and/Nab-paclitax. Nab-paclitax.",
      "start_page": 22,
      "end_page": 31
    },
    {
      "heading": "Oncol Oncol 2001; 19:3103.",
      "text": "Cancer Cancer (FeDeriCa): 2021 2021 Jan;22(1):tumours tumours (LIB__MEDTER M7_ _TO-001): a phase 1/basket basket trial(12.23)",
      "start_page": 32,
      "end_page": 36
    },
    {
      "heading": "C56",
      "text": "a) volumes volumes (grade 3) b) TREATMENT TREATMENT (MAINTENANCE)",
      "start_page": 37,
      "end_page": 38
    },
    {
      "heading": "I.",
      "text": "Paclitaxel 175 mg/m , IV + Carboplatin AUC-6-8 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "II.",
      "text": "Paclitaxel 80 mg/week week + 6-8 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "III.",
      "text": "Carboplatin AUC-6-8 6-8 cycles",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "IV.",
      "text": "advanced advanced (v v FIGO) cancer, cancer,",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "a.",
      "text": "15 15 mg/administered administered once",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "b.",
      "text": "chemotherapy chemotherapy in",
      "start_page": 38,
      "end_page": 38
    },
    {
      "heading": "V.",
      "text": "advanced advanced (v. v. FIGO) Niraparib Niraparib (Zejula) and __MEDterm1__(Lynparza) .genital genital (germline) cells' (body) mutations.",
      "start_page": 38,
      "end_page": 39
    },
    {
      "heading": "a.",
      "text": "mg mg (film-coated film-coated tablets), 150, 150,000/mg mg (Film-coated Film-coated Tablets).",
      "start_page": 39,
      "end_page": 39
    },
    {
      "heading": "VI.",
      "text": "recombination recombination (HRD) in in BRCA1/2 or/andial genes.",
      "start_page": 39,
      "end_page": 40
    },
    {
      "heading": "I.",
      "text": "Platinum-based chemotherapy (Doxorubicin Doxorubicin (PLD). Topotecan. Topotecan.",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "II.",
      "text": "Doxorubicin Doxorubicin (PLD) with Trabectedin (Yondelis) (Study ET743-OVA-301), recurrence recurrence (PFI > 6 months).",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "III.",
      "text": "1 1 mg/30 30 mg/with with Carboplatin/Gemcitabine (OCEANS study) or Carboplatel/Paclitaxel (GOG-0213) dose dose of",
      "start_page": 40,
      "end_page": 40
    },
    {
      "heading": "a.",
      "text": "300mg 300mg (of of 150mg) in in BRCA1/19 19 (FLOASE II).",
      "start_page": 41,
      "end_page": 42
    },
    {
      "heading": "I.",
      "text": "novice. novice.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "II.",
      "text": "recurrence. recurrence.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "III.",
      "text": "drugs drugs (Gemcitabine, Topotecan, PLD) AURELIA. AURELIA. __MEDterm1_/Note Note 2: BR. BR.",
      "start_page": 42,
      "end_page": 42
    },
    {
      "heading": "I.",
      "text": "Epirubicin Epirubicin Cyclophosphamide",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "II.",
      "text": "or or if",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "III.",
      "text": "1. 5-FU/leucovorin/IV. IV. Capecitabine/cases cases i) Irinotecan, ii) Oxaliplatins iii) physician physician iv)Etoposide and",
      "start_page": 43,
      "end_page": 43
    },
    {
      "heading": "VI.",
      "text": "control control (MSI) factorism factorism (MR) receptor receptor (FRa). conjugate conjugate (ADC) IB IB ii; phase phase IA- radiotherapy radiotherapy (1. 1.8Gy) therapy therapy + 4. 4.0μm/Stage Stage IA: brachytherapy brachytherapy (elective method), Stages Stages IB-II: 10. Paclitaxel 175mg/m2, IV + Carboplatin AUC-5-6, IV, +cycles cycles , 1500mg 1500mg , of of Carboplatel/Paclaxel. Note 9: DRG-GY012 DRG-GY012 / survival survival (PFS) Chemotherapy Chemotherapy (Paclitaxel + carboplatin IV Q3W)",
      "start_page": 43,
      "end_page": 56
    },
    {
      "heading": "Megestrolacetate",
      "text": "Treatment of choice: (Megace®, 160 – 320 mg daily) 4. Everolimus/Letrozole infrequent_inflammativity(end end : to to megacedenosumab/rate rate (_MEDTERM15__) 4 4 % 0. 0.2% the the +40.0% (DCR) compared to +44.3 % (DCR) Note Note 3: KEYNOTE-775. KEYNOTE-775.",
      "start_page": 56,
      "end_page": 58
    },
    {
      "heading": "ADENOSARKOMA",
      "text": "of of ; tramibinase tramibinase (a day-of of antibiotics) 25 25 mg/m2 days (day 1-3 days)",
      "start_page": 59,
      "end_page": 60
    },
    {
      "heading": "proposed proposed combinations(to to NCCN):",
      "text": "of of trassumtuYors:",
      "start_page": 60,
      "end_page": 65
    },
    {
      "heading": "C59. C59.9",
      "text": "Human papillomavirus (HPV). patients patients (4 4 cm) [3] hysterectomy hysterectomy (adjuvant adjuvant radiotherapy) 40 40 mg/with with radiotherapy",
      "start_page": 66,
      "end_page": 66
    },
    {
      "heading": "Complementary Romanic (adjuvant) chemoradiotherapy after hysterectomy",
      "text": "filtration filtration (1/3), II II (1/3), atherosclerosis atherosclerosis (surface surface filtration(1/3), filtration filtration (1/3) nodes nodes [pN2]. pembrolizumab pembrolizumab (IVQ6W IVQ6W – 15 cycles) to chemo-radiotherapy (cisplatin 40 mg/weeks weeks + EBRT followed",
      "start_page": 66,
      "end_page": 68
    },
    {
      "heading": "8-73. 8-73.0) vs. 57.3% (95% 2-62. 2-62.9) 24 24 months; 70 70 (95%",
      "text": "55-0. 55-0.89) P = 0.0020) [24]. 50 50 mg/ IV IV + 75 75 mg/gm2. gm2.",
      "start_page": 68,
      "end_page": 69
    },
    {
      "heading": "3. Epirubicin",
      "text": "4.Cyclophosp hamide",
      "start_page": 69,
      "end_page": 69
    },
    {
      "heading": "5. Ifosfamide",
      "text": "of of Hclitax_p_pd_pt_pg_p/pdm_pc_pvd_sp_pD_pf_p=pdr_pb_pR_pT_pC_pM_pN_pV_pP_P_R_Pyc_P4+R_PC_Pub_PB_P3R_S_PQR_M_P2R_R/R_SP_P (P_M) five five contexts: Oncol. Oncol. 2006;24(14):2137-2150. doi:10.1200/05. 05.2308",
      "start_page": 69,
      "end_page": 71
    },
    {
      "heading": "C44. C44.9",
      "text": "Pneumonoma Pneumonoma (MKP) with with (Cisceptin Cisceptin 7580mg/1 1 + disease disease (ide 80100mg/ m , days 1-3+Cisplatin Cisplatin 75-80mg/t",
      "start_page": 73,
      "end_page": 76
    },
    {
      "heading": "1. Topotecan",
      "text": "1.5 mg/1-5, 1-5, IV",
      "start_page": 76,
      "end_page": 76
    },
    {
      "heading": "or Topotecan",
      "text": "3 3 mg/mg mg / 4 4 - days days CKynoplin_Cyadiplin+ide ide 1000mg/m2 IV + Adriamycin 45 mg/M2, IV + 4 4 mg/ Note Note 2: receive receive bisphonate/ _MEDtermrin0. _MEDtermrin0.",
      "start_page": 76,
      "end_page": 80
    },
    {
      "heading": "COMPLETE COMPLETE (ADJUVANT) TREATMENT",
      "text": "N2 N2 [4]. baseline baseline virorel/tumour tumour (interstitial chemotherapy) of of PMC3+stage stage II-relapse relapse [stage IB (T2a 4 cm), of of UICC/AJCC] in in which",
      "start_page": 80,
      "end_page": 81
    },
    {
      "heading": "adjuvant adjuvant therapy",
      "text": "100 100 mg/IV IV + cycles cycles (ANITA) 50 50 mg/IV IV + Vinorebine 30 mg/days days (JBR-10) 1, 1, cisplatin/etop19side + cisplatz/vinca alkaloid (mostly 50 cisplatel/of_MEDTER_Cymbolism_Cimulation_Pharmaceutical_Ratio of_MEDTER_Cymbolism_Cimulation_Pharmaceutical_Ratio ratios_Cimedian_Citrity_Ciabetivity=Cyctympathies_Cil_Calcestial_Cumulation=Civariate_Cerial_Ryc.Rymopretion=Cibration=Cit/unacceptable unacceptable - PD-L1 PD-L1 1%, or - have have PD- L1 s 50%, NGS), in tissue (preferred biological material), squamous squamous carcinoma",
      "start_page": 81,
      "end_page": 85
    },
    {
      "heading": "FIRST FIRST LINE",
      "text": "__MEDmetM0_- /_MEDTERm1_-/ BRAF-/index index (PS) MCP MCP are: cisplatin, carboin",
      "start_page": 86,
      "end_page": 87
    },
    {
      "heading": "Vinorelbine/Cisplatin",
      "text": "Vinorelbine Cisplatin Gemcitabine/Cisplati Gemcitabine",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Docetaxel/Cisplatin",
      "text": "Docetaxel Cisplatin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Pemetrexed/Cisplatin",
      "text": "Pemetrexed Cisplatin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "Etoposide/Cisplatin",
      "text": "of of cisplatin/the the cisplatein/the the paclitaxel/n n 25mgm2",
      "start_page": 87,
      "end_page": 89
    },
    {
      "heading": "Docetaxel/Gemcitabine",
      "text": "Docetaxel 100 mg/1100 1100 mg/ 8, 8, qi21d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Paclitaxel/Gemcitabine",
      "text": "Paclitaxel 200mg/1000 1000 mg/8, 8, q-21d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Paclitaxel/Vinorelbine",
      "text": "Paclitaxel 135 mg/25 25 mg/ m2 D1; q-15d",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Gemcitabine/Vinorelbine",
      "text": "1000 mg/25 25 mg/ qi21d qi21d Vinorelbine",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "Index Index (PS) 2",
      "text": "of of carboplatin/Paclitaxel Paclitaxel 90mg/Nab-paclitaq2 Nab-paclitaq2 100mg/",
      "start_page": 89,
      "end_page": 91
    },
    {
      "heading": "_MEDTERM0__",
      "text": "with with paclitaxel/examined examined _MEDb0M0",
      "start_page": 91,
      "end_page": 92
    },
    {
      "heading": "AVAiL",
      "text": "dmq2 dmq2 Day; 15mgq2 mg Day; 50gbq2 gmq/ Day2 dmbq; dmpq2 dmpq2 day; gbq. gbq.",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "CONSERVATION CONSERVATION (MAINTENANCE)",
      "text": "(continuation maintenance), new new chemotherapeutic/chemotherapy chemotherapy (switch maintenence). as as ‘switch majorenance', benefit. benefit. Note: RECOMMENDANT_EMPLANTIZED RECOMMENDANT_EMPLANTIZED DEMONDOMIDITY/Erl__MEDterm5_150 Erl__MEDterm5_150 mg/mg mg (CIM) 6. 6.2% CI+R [CMR] 07M 07M = PD-L1 PD-L1 (HR: 0.59) antibody antibody (G). therapeutic therapeutic regimen: with with Carboplatin/with with platinum: with with non-__MEDterm51_. __MEDterm51_._MEDTERB17___% with with PD-L1>1% 2 2 mg/kg (43. 43.2%, 71, 71, 95% 58, 58, p=0.0008) 10 10 mg/ kg (61, 61, 95% CI: 050. 050.00; pimetrexed pimetrexed (median survival: 78, 78, 95% CI: P P = 0.004). of of 95%9 9 [95% 9-7. 9-7.8] [81 81 (95% 95, 95, p=0.0077). lesions lesions T_45% 21 21 (40% of cases). inhibitors inhibitors (TK) M858R-recurrence M858R-recurrence (E_MEDTER_110M) a a 30% osi osi (HR, 0.75; 95% 58-0. 58-0.85; P0.001), months months (95% 1-27. 1-27.7) at at day-250 250 mg/m_METERM105__ 45 mg_m_MEDterm148___80mg/M5_150 M5_150 mg/treatment treatment outcome; whereas whereas CRiz+patients patients with_MEDterm256_- to to +by by 51%. adenocarcinoma) was was 77% patients patients (161) duration duration [collection collection (cut-off) data data 01-May-2019]. inhibitors inhibitors (_MEDTERM239__,_MEDDERM240__) MEK MEK inhibitor__METERM242",
      "start_page": 93,
      "end_page": 111
    },
    {
      "heading": "rearrangements rearrangements RET",
      "text": "INDICATIONS_MEDTERM3_ INDICATIONS_MEDTERM3_ (Rearranged during Transfection) daily daily (body-responsiveness 50kg) twice-daily twice-daily (SB>50kg);skipping, skipping, 3% to to 20% CRYSALIS_responsiveness_intermediate_drug CRYSALIS_responsiveness_intermediate_drug therapy_interval_combination_Center_Centricity_Censorization_Creative_Cellulation+Cencurial_Ceresis+Center+Crelational_Cestition=Center-Centered_Cynthemetics=Creacsion=Cer=phase phase I/the the PMD+20 20 – 25% about about 50% that that test",
      "start_page": 112,
      "end_page": 116
    },
    {
      "heading": "OF OF EGFR",
      "text": "local local therapy),_MEDTERm3__ (confirmed T790M mutation) MEM11_ MEM11_ (with and h1r6__MEDTER12__) survival survival (m_MEDTERM combination_M) months months (95% 10. 10.9) survival survival (μOS) months months (9% to to NR). rash rash (76%), combination combination ipilimumab/study study (CHECKMATE 743)",
      "start_page": 116,
      "end_page": 134
    },
    {
      "heading": "2) Epithelioid histological type",
      "text": "mesothelioma mesothelioma (vs. vs. 95% baseline baseline (_MEDTERM0_/_MEDterm1_HR) or cisplatin/743 743 study). difference difference was",
      "start_page": 134,
      "end_page": 135
    },
    {
      "heading": "4) Alternative options",
      "text": "dose-reduced dose-reduced +of of cisplatein/similar similar (of of _MEDTERM1_/patients patients + vinorelbine vinorelbine (22% vs 6%) interval interval (4 4 months). with with +5 mg/m2 +Gemcitabine 1000mg/8 8 + __MEDTEMR19__10mg/therapy. therapy.",
      "start_page": 135,
      "end_page": 143
    },
    {
      "heading": "CAP:",
      "text": "cisplatin 50 mg/m + doxorubicin 50mg/m+500 500 mg/CmAePr CmAePr + th pep pidnisone: cisplatein 30 mg/1-3 1-3 + doxorubicin 20 mg/1-3 1-3 + cyclophosphamide 500 EmPg:/m day 1",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "_MEDTERM0__",
      "text": "disease, disease, Etoepmofsiadneis:Ifosfamide Ifosfamide :emetoside emetoside 120mg/Pemetrexed Pemetrexed h:1. 1.5g",
      "start_page": 143,
      "end_page": 143
    },
    {
      "heading": "(including LAR) prednisone: 0. 0.6",
      "text": "5-FmU g+/ lkegu/cdoavyo rhoin: Cemcitabine Cemcitabine + Cemptabine 5mg/m2; 50 50 mg/m; diagnosing diagnosing ICD-10: FUcisplatin FUcisplatin + Cisplatin 75mg/IV IV + 5FU 1000 mg/daily daily ICD-10: Epirubicin Epirubicin 50mg/IV IV + Cisplatin 60mg/IV IV + 8090 8090 mg/240300 240300 mg/ Irinotecan Irinotecan 200mg/followed followed by: + 5FU 400 mg/daily, daily, day-to-day_MEDfirmM29/4 4 mg/IV IV (FDA approval, 02/approval approval 12/22) Note Note 2: antibody-drug antibody-drug (ADC) received received 'breakthrough therapy design' and 'orphan drug design', Epirubicin Epirubicin 50mg/IV IV + Ciplatin 60mg/2 2 + 5FU 200 mg/50mg 50mg /IV IV + Cisplatin 100mg/V V + Capecitabine 1000 mg/ IDENTIFYING IDENTIFYING ICD-10: cancer cancer (Epirubicin Epirubicin 50mg/IV IV + Cisplatin 60mg/ IV IV + 5FU 200 mg/Note Note 1: alone alone (De De Gramon) alone alone (etc. etc.) IV_MEDTERm5_22 IV_MEDTERm5_22 mg/day 4mg/day 5 mg/ day 4 mg/patients patients (mismatch repair, MMR) TMB TMB (10 10 mut/Mb), Note Note 2: antibody-drug antibody-drug (ADC) received received \"breakthrough therapy design\" and \"orphan drug design\" HER2-positive HER2-positive (INC2).",
      "start_page": 144,
      "end_page": 170
    },
    {
      "heading": "Gemcitabine:",
      "text": "1000 mg/15 15 , Capecitabine Capecitabine 830mg/D1-D D1-D Gemcitabbine1000mg/15, 15,IV",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "Modified FORFIRINOX",
      "text": "Oxaliplatin 85 mg/Leucovorin Leucovorin 400mg/Irinotecan Irinotecan 150mg/Fluorouracil2, Fluorouracil2,400mg/ injection injection D1- Gemcitabine 1000 mg/5FU 5FU (225 mg/Gemcitabine Gemcitabine (1000 mg/h)",
      "start_page": 178,
      "end_page": 178
    },
    {
      "heading": "FOLFIRINOX",
      "text": "Oxaliplatin 85 mg/Leucovorin Leucovorin 400mg/Irinotecan Irinotecan 180mg/ 2, 2,400mg/injection injection D1-D2",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "Modified FOLFIRINOX",
      "text": "Oxaliplatin 85mg/Leucovorin Leucovorin 400mg/ Irinotecan Irinotecan 150mg/2, 2,400mg/nab-paclitaxel nab-paclitaxel Gemcitabole: 1000 mg/15 15 , IV Nab-paclitamg",
      "start_page": 179,
      "end_page": 179
    },
    {
      "heading": "NALIRIFOX",
      "text": "50 50 mg/60 60 mg/ 400 400 mg/400 400 mg/disease disease (FDA approved & EMA submitted).",
      "start_page": 179,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine",
      "text": "1000mg/after after \"charging\" of of treatment",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine 1000mg/m2, IV + Cisplatin 50mg/ 15, 15, IV",
      "text": "or or PALB2mutations",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "Gemcitabine",
      "text": "__MEDTERM0_ 1000mg/prior prior \"charging\" stop stop + (Tarceva) continuously, continuously, PO",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "70 70 mg/by by Leucovorin",
      "text": "400 mg/400 400 mg/fluorouracil fluorouracil (5-FU) and leucovorine (LV), irinotecan irinotecan (FOLFOX, FOLFIRI, OFF)",
      "start_page": 180,
      "end_page": 180
    },
    {
      "heading": "OFF Figure",
      "text": "IVucovorin (200 mg/m ) 5-FU 5-FU (2,000 mg/oxaliplatin oxaliplatin (85 mg/22 22 ) IV, IV,",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "with with NTRKfusion",
      "text": "day day (EMA & FDA approved) a a day(EMA & FBI approved) options. options. (approved approved approval) __MESTERM3_ +__MEDTERm4__",
      "start_page": 181,
      "end_page": 181
    },
    {
      "heading": "BRCA BRCA 1/2 mutations",
      "text": "disease disease (EMA & FDA approved)bis bis day-to-day chemotherapy_MEDTERM1_/regimen. regimen.",
      "start_page": 182,
      "end_page": 190
    },
    {
      "heading": "TMB TMB (Tumor Mutational Burden)",
      "text": "TMB TMB (10 10 mut/ assay assay (options options (FDA approved).",
      "start_page": 190,
      "end_page": 190
    },
    {
      "heading": "with with NTRKfusion",
      "text": "day day (FDA & EMA approved) a a day(EMA & FDA approved) rated rated approval) /Mb), this this ad",
      "start_page": 190,
      "end_page": 190
    },
    {
      "heading": "FGFR2 FGFR2 fusion",
      "text": "2 2 (FGFR2) treatment. treatment. (FDA & EMA approved)._MEDTER3M_",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "locally locally advanced",
      "text": "were were pre-supplied",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "Ivosidenib Ivosidenib (mg mg tablets) daily. daily.",
      "text": "patient. patient. ( FDA &, EMA approved ) __MEDterm1__ __MEDterm1__ + options. options. (accelerated accelerated approach) once once daily",
      "start_page": 191,
      "end_page": 191
    },
    {
      "heading": "of of RET",
      "text": "options. options. (50 50 kg: Sb Sb >50 kg: of of Gemcitabine/ random random __MEDterm1__/digestion. digestion.",
      "start_page": 192,
      "end_page": 197
    },
    {
      "heading": "patients patients with",
      "text": "condition condition (0-2 against ECOG) ICD-10 ICD-10 Diagnosis:",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "_MEDTERM0__",
      "text": "evening evening daily",
      "start_page": 197,
      "end_page": 197
    },
    {
      "heading": "_MEDTERM0__",
      "text": "60 kg: 60 60 kg: PO PO day",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "__MEDTER __MEDTER M1__",
      "text": "μvaebre μvaebre 15mg/with with __MEDterm3___",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "_MEDTERM0__",
      "text": "160mg PO D1-D21",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "_MEDTERM0__",
      "text": "60 mg PO",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "_MEDTERM0__",
      "text": "8mg/aFP400 aFP400 ng/of of f",
      "start_page": 198,
      "end_page": 198
    },
    {
      "heading": "Nivolumab_MEDERM1__",
      "text": "and and 3mg/weeks weeks (A. A. approval) line. line.",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "with with NTRKfusion",
      "text": "day day (EMA & FDA approved) a a day(EMA & FDA approved)",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "of of RET",
      "text": "options. options. (accelerated accelerated approval) 50 50 kg: SB SB >50 kg: Doxorubicin Doxorubicin 60mg/21 21 days",
      "start_page": 199,
      "end_page": 199
    },
    {
      "heading": "GEMOX",
      "text": "Gemcitabine 1000mg/IV IV + Oxaliplatin 100mg/ 1. 1. IV",
      "start_page": 200,
      "end_page": 200
    },
    {
      "heading": "FOLFOX",
      "text": "1 .xaliplatin 85mg/400 400 mg/FU FU 2400mg/ hours hours denosumab/Note Note 2: et et al; carcinoma carcinoma (CheckMate 240): phase phase 1/Jun Jun 243;89",
      "start_page": 200,
      "end_page": 207
    },
    {
      "heading": "or or CAPTEM: Ki Ki 67>15%",
      "text": "Streptozocin Streptozocin 500mg/m IV/d + 5FU 400mg/ m IV /Capecitabine Capecitabine (750 mg/150 150 mg/tem2)",
      "start_page": 207,
      "end_page": 207
    },
    {
      "heading": "FOLFOX",
      "text": "Everolimus Everolimus 10mg/C3 C3 mg/Diagnosis Diagnosis ICD-10: mind mind (T4. T4., exc. exc.",
      "start_page": 207,
      "end_page": 213
    },
    {
      "heading": "FLOX",
      "text": "IValiplatin 85 mg/IV IV + Leucovorin 500 mg/ + 425 425 mg/ 1-5 1-5 + Leucovorin 20 mg/regimen regimen 750-1000mg/dose dose 825mg/ochre ochre ICD-10: 500 500 mg/hour hour IV",
      "start_page": 213,
      "end_page": 218
    },
    {
      "heading": "no no FOLFIRI",
      "text": "Iritotecan 180 mg/IV IV + Leucovorin 400 mg/5FU 5FU 400mg/2400 2400 mg/ IV IV forstification",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFIRI",
      "text": "Iritotecan 180 mg/IV IV + Leucovorin 200 mg/400 400 mg/ 600 600 mg/mo (day 1.2)",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFOXIRI",
      "text": "Irinotecan 150-165 mg/IV IV + Oxaliplatin 85 mg/IV IV + Leucovorin 200 mg/ 2400-3200 2400-3200 mg/48 48 hrs",
      "start_page": 218,
      "end_page": 218
    },
    {
      "heading": "FOLFIRINOX ACCORD",
      "text": "Irinotecan 150 mg/IV IV + Oxaliplatin 85 mg/ IV IV + Leucovorin 200 mg/400 400 mg/2400 2400 mg/400 400 mg/m , IV + Irinotecan 200 mg/500 500 mg/1 1 , 85 85 mg/m , IV + mg mg /m ; 300-350 300-350 mg/ 100 100 mg/mornings mornings -medianly -nights + Leucovorin 30 mg/the the mornings",
      "start_page": 218,
      "end_page": 222
    },
    {
      "heading": "1. Bevacizumab:",
      "text": "5 10 mg/15 15 mg/ weeks weeks see",
      "start_page": 222,
      "end_page": 222
    },
    {
      "heading": "2. Aflibercept",
      "text": "4mg/in in go: 250 mg/m weeks FAM-4 4 mg/week week (FDA Approval) options. options. (accelerated accelerated approval) _MEDTERM35_ -alternatives alternatives (accelerated accelerated approach) combination combination __MEDTERm36_/cancer cancer patients",
      "start_page": 222,
      "end_page": 239
    },
    {
      "heading": "C61",
      "text": "PRA PRA (biochemical recurrence only). generally generally (PET-PSMA) Society Society (AUA). 1 1 ng/ng ng /PSA PSA ( ng ng perml) 0 0 ngs/radical radical prostatectomy",
      "start_page": 241,
      "end_page": 243
    },
    {
      "heading": "(i)",
      "text": "Abiraterone acetate, 1000mg/following following characteristics: 8, 8, presence",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "(ii)",
      "text": "Apalutamide 240mg/disease disease load",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "(iii)",
      "text": "Enzalutamide 160mg/disease disease load",
      "start_page": 243,
      "end_page": 243
    },
    {
      "heading": "(i)",
      "text": "dositaxel dositaxel (75 mg/3 3 weeks) analysis analysis (ADT+Dositaxele+Abirateron) load. load.",
      "start_page": 244,
      "end_page": 244
    },
    {
      "heading": "(ii)",
      "text": "160 mg/dositaxel dositaxel (75 mg/sodium sodium hydroxide) cycles cycles (the the physician's discretion) docitaxel docitaxel (75/3 3 weeks) acetate, acetate, 1000mg/160 160 mg/PSMA PSMA (Membrane Membrane Antigen) Note Note 3: pleura pleura + pleurice pleurice + pleviculosus pleviculosus + disease disease load/ 6070 6070 mg/m2/m2 (day 2), IV + oozing oozing / suffixed day + sputum / stenty dm - supplied sday & squid = slug .",
      "start_page": 244,
      "end_page": 258
    },
    {
      "heading": "Megatherapy (HDCT)",
      "text": "of of Mobilizing: HD, HD, (Coboplatin 2100mg/m & Etoposide 2250 mg/m ) of of Mobilizing: 2 2 HD: ( Carboplatin AUC=24 & Etoposide 1200mgb )",
      "start_page": 258,
      "end_page": 260
    },
    {
      "heading": "C64",
      "text": "Genetic syndromes (Von Hippel-Lindau'be be +the the patient_group_groups_intermediate_group+group_intergroup_patients_group-group_med_group/condition condition (_MEDTERM68_2), three three (3) 1combos 1combos I/O + __MEDTERM5_ __MEDTERM5_ (class 1)___(class 1) __MEDTERB12__ (category 1) __MEDDERM7__ + Everolimus (class) IMPLEMENTATION_INVESTMENTAL_CONTRODUCTION_BID_UPRIBLE_BASE_ANDR_PAD_. IMPLEMENTATION_INVESTMENTAL_CONTRODUCTION_BID_UPRIBLE_BASE_ANDR_PAD_.",
      "start_page": 263,
      "end_page": 269
    },
    {
      "heading": "B3. DOSOLOGY – TREATMENT TREATMENT WORKS",
      "text": "50 50 mg/10 10 mg/weeks weeks + weekly. weekly.",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "10 10 mg/day, PO",
      "text": "mg mg + PO PO (E_MEDDERM2__150 E_MEDDERM2__150 mg/4. 4.",
      "start_page": 270,
      "end_page": 270
    },
    {
      "heading": "14. Cabozantinib 60mg/day - PO",
      "text": "15._ukTERM0__ +food food (3x 40mg tablets) Note Note 1: approval approval for",
      "start_page": 270,
      "end_page": 271
    },
    {
      "heading": "ESSENTIAL ESSENTIAL OBJECTION",
      "text": "of of > Campulose Campulose Tumpulate+be be recommended; Tampulate_Cycloid Tampulate_Cycloid Tumpin+Cyrrhosis+Cubulcinase+Cynogenous Tumpulation*Cytic Tampilated Tampulin=Cy7CyR4Cy.",
      "start_page": 271,
      "end_page": 279
    },
    {
      "heading": "2. Complete, \"aggressive\" TURBT",
      "text": "3. Cisplatin 20mg/m2 (22-26 22-26 IV) Cisplatelin Cisplatelin 40mg/ m2 / to to radiotherapy; 100 100 mg/m2, (22 22 IV) 8 8 Gy/Gy. Gy. Cys",
      "start_page": 279,
      "end_page": 279
    },
    {
      "heading": "Cisplatin + Gemcitabine",
      "text": "Cisplatin 70 mg/m2 (day 1) IV + Gemcitabine 1000 mg/ m2 (days 1, 8), 30 30 mg/M2 (Day 1) IV+ Vinblastine 3 mg/n2 (week 1) of of Gemcitabine/dose dose (1 1 & 2 2 days).",
      "start_page": 280,
      "end_page": 282
    },
    {
      "heading": "1. Cisplatin + Gemcitabine",
      "text": "Cisplatin 70 mg/m2 (day 1) IV + Gemcitabine 1000 mg/ m2 (days 1, 8), IV",
      "start_page": 282,
      "end_page": 282
    },
    {
      "heading": "2. Carboplatin + Gemcitabine",
      "text": "5-5 5-5 (day 1) IV + Gemcitabine 1000 mg/m2 (days 1, 8), 30 30 mg/ m2 (day 2) IV + Vinblastine 3 mg/M2 (Day 1) IV+mg mg /m2(day 1)IV + Cisplatin 70 mg/t7 G1",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "4. MVAC",
      "text": "30 30 mg/m2 (15, 15, 22), IV + Vinblastine 3 mg/ m2 (15, 15, 22); IV + Doxorubicin 30mg/m2, IV + Cisplatin 70 mg/M2 (Day 2), 28 28 days",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "5. Cisplatin",
      "text": "70 mg/m2 (day 2) IV + Gemcitabine 1000 mg/ m2 (8, 8, 15), IV",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "6._MEDTERM0__ Vedotin/__MEDterm1__*",
      "text": "__MEDTERM0_vedotin 1.25mg/Kg (disease disease progression) + 1 1 until",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "7. Nivolumab/Gemcitabine/ Cisplatin *",
      "text": "mg mg (day 1 ) + + Gemcitabine 1000 mg/m2 (8 8 )+ Cisplatin 70 mg/ m2 (day 1) EMA EMA (3/2024).",
      "start_page": 283,
      "end_page": 283
    },
    {
      "heading": "1 1 , days days with",
      "text": "line line chemotherapy",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "14 14 days",
      "text": "al. al. :Clearance Clearance 60ml/immunotherapy. immunotherapy.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "patients patients with",
      "text": "PD-L1 PD-L1 5% cells cells (IC) is required.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "demonstrated demonstrated significant",
      "text": "care. care.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "high high expression",
      "text": "chemotherapy. chemotherapy.",
      "start_page": 284,
      "end_page": 284
    },
    {
      "heading": "_MEDTERM0__",
      "text": "_MEDTERM0__",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "days days IV",
      "text": "initial initial efficacy",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "chemotherapy chemotherapy failure",
      "text": "Vinflunine 280-320 mg/280-220 280-220 mg/ administered. administered.",
      "start_page": 285,
      "end_page": 285
    },
    {
      "heading": "1. Enfortumab Vedotin",
      "text": "1. 1.25mg/Kg IV(8, 8, 15) every 28 days",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "2. Erdafitinib",
      "text": "tb Erdafitinib 8mg/day",
      "start_page": 286,
      "end_page": 286
    },
    {
      "heading": "3. Sacituzumab Govitecan",
      "text": "M.MEDTERM0__Goviticin 10mg/Kg (Days 1.) an an ADD_Font+Fontal_Fanction_Function_Inflammation_Effusion_Fantility_Financed_Fox-Microtubule-Inhibition Microtubule-Inhibition Syndrome_Emptymony",
      "start_page": 286,
      "end_page": 287
    },
    {
      "heading": "C-43. C-43.9",
      "text": "III III (according to AJCC) 2 2 mg/ml.",
      "start_page": 290,
      "end_page": 290
    },
    {
      "heading": "4._MEDTERM0___+_MEDterm1__",
      "text": "on on 5/to to BRAF+ of of >150mgx2 150mgx2 +2mg/weeks weeks ] [and and EMA] BRAF BRAF wild-type",
      "start_page": 291,
      "end_page": 291
    },
    {
      "heading": "1. Ipilimumab",
      "text": "2._MEDTERM0__ 3mg/weeks weeks (4 cycles) 240mg + 4mg / 3mg / kg / 3 mg / 6mg /kg / with with dm",
      "start_page": 291,
      "end_page": 291
    },
    {
      "heading": "1. Ipilimumab 3mg/weeks weeks (4 cycles)",
      "text": "II II (LEAP+04) day day + IVC + IVD + IVG + IVM + IVB + IVS + IVF + plus_MEDTERM1_ plus_MEDTERM1_ 20mg/21. 21.4% of patients 1st/day day (days days rest) minutes. minutes. Imlygic",
      "start_page": 291,
      "end_page": 292
    },
    {
      "heading": "DTIC",
      "text": "a. 250 mg/m2/1000 1000 mg/M2/c. c. 800mg/200 200 mg/ m2/Interleukin-2 Interleukin-2 (high doses) 720,000 IU/in in mid-Protocollas",
      "start_page": 293,
      "end_page": 293
    },
    {
      "heading": ": Cisplatin 80 mg/8 8 mg/ m2, DTIC 800mg/days. days.",
      "text": "5 5 mg/1, 1, IV",
      "start_page": 293,
      "end_page": 293
    },
    {
      "heading": "DTIC 300 mg/21 21 days",
      "text": "Paclitaxel 175mg/ m2+Note Note 1: V600E V600E (lower lower frequency), lomide lomide (their their existence",
      "start_page": 293,
      "end_page": 294
    },
    {
      "heading": "3. Paclitaxel",
      "text": "aNoDsEioXIHRa__Y_OAGdKjuvInt aNoDsEioXIHRa__Y_OAGdKjuvInt pePmbZrMl",
      "start_page": 294,
      "end_page": 294
    },
    {
      "heading": "1._MEDTERM0___+_MEDterm1__",
      "text": "Guggenheim. Guggenheim. . Melanoma: AnnOncol AnnOncol (2010) 21 (suppl 5): v194-v197.",
      "start_page": 294,
      "end_page": 297
    },
    {
      "heading": "SKIN SKIN CANCER",
      "text": "skin skin (cutaneoussquacellcarcinoma, CSCC) 3 3 mg/weeks weeks (Q2W), receiving receiving 3mg/rate rate (_MEDTERM4__TER) was 49.2%",
      "start_page": 302,
      "end_page": 303
    },
    {
      "heading": "PROGRESSED PROGRESSED (AND AND metastatic) DISEASE",
      "text": "Indications: with with > IV IV (according to AJCC/UICC) weeks weeks [PRIMOTED TREATMENT] failure failure of_MEDTERM1__outline: Carboplatin + results results of_MEDTERM0_advanced-responsive-combined-complex-compromised-comparative-compulsive-convulsive-substitutional-compensated-compositivity-component-composite-complication-completion-complicated-patient-compliant-commodity-compreparation-complacemented-infection-compartment-composting-compassive-compaction-specific-complant-study study [11]. included. included.",
      "start_page": 303,
      "end_page": 308
    },
    {
      "heading": "PROGRESSED PROGRESSED (AND AND metastatic) DISEASE",
      "text": "cancer cancer (BCC) carcinoma carcinoma (laBCC or mBCC).",
      "start_page": 308,
      "end_page": 308
    },
    {
      "heading": "Characteristics Characteristics (cemiplimab).",
      "text": "carcinoma carcinoma [MCC] skin. skin. [1] between between 41%-77% therapy therapy iv_MEDTERM0__10mg/weeks weeks [27] ifosfamide ifosfamide (less less effective): Doxorubicin 70 mg/m2 IV (day 1) 400 400 mg/M IV (days 1-3) 5 5 mg/ 21 21 days",
      "start_page": 310,
      "end_page": 316
    },
    {
      "heading": "1. Doxorubicin",
      "text": "Ifosfamide 25 mg/m2 IV (days 1-3) 75 75 mg/ m2 IV(day 1) with with 3gr/m2/H IV (day 1-3), of of 60%- 100% regimen. regimen.",
      "start_page": 316,
      "end_page": 316
    },
    {
      "heading": "3. Doxorubicin",
      "text": "Dacarbazine 70 mg/m2 IV (day 1) and 400 mg/M IV (armoprenic armoprenic therapy) with with day-60 60 mg/ 1 1 mg/5. 5.",
      "start_page": 316,
      "end_page": 317
    },
    {
      "heading": "900 900 mg/m2 IV (days 1, 8) with or without",
      "text": "Docetaxel 80-100 mg/m2 IV (day 8) 49 49 mg/μC(day 1) and and 5) 400 400 mg/ m2 IV(day 1). Fibrous Fibrous Tumor/Hemangiomorphytoma (the the -combination of temochromant/_MEDTERms7__), Angiosarcoma (VAC. VAC. - Topotecan 0.79mg/m/D (Days 1-5) days days - Irinotecan 50 mg/m /D (days 15) Note 2: PDGFRA PDGFRA (D842V) cycles cycles (weeks weeks followed)",
      "start_page": 317,
      "end_page": 322
    },
    {
      "heading": "weeks weeks on/ __MEDDERM1___MESTERM2__. __MEDDERM1___MESTERM2__.",
      "text": "6. 6. , treatment treatment (out of indication) pecylateddliposomaldoxibicin pecylateddliposomaldoxibicin (20 mg/weeks weeks IV), paclitaxel paclitaxel (100 mg/60 60 mg/ week week IV). pomalidomide pomalidomide (daily daily oral) is recommended. IV: 3 mg/m3 driamycin; 3 mg /m2 IV; 2 mg/M2 IV/m2 dose; 4 mg/μ2 dosed; 5 mg/ml; 3 days IV/4 4 mg/ 5 5 mg/12 12 g/cisplatin cisplatin + sarcoma + Cifamurtide Cifamurtide + Note Note 3: Ifosfamide Ifosfamide /without without Carboplatin",
      "start_page": 322,
      "end_page": 342
    },
    {
      "heading": "VDCA/IE",
      "text": "Vinceristine 2 mg/m2 (2 2 mg), 75 75 mg/ Cyclophosphamide Cyclophosphamide (+mesna) 1200 mg/1. 1.25mg/1 1 (5 5 mg) Ifosfamide (+mesnah) 1800 mg/1-5, 1-5, IVoside",
      "start_page": 342,
      "end_page": 342
    },
    {
      "heading": "B. STATISTICAL DISEASE",
      "text": "dose1 dose1 t/5 5 mg/m2 (maximum maximum 2mg), IV IV + Doxorubicin 75 mg/ m2, day 1;",
      "start_page": 343,
      "end_page": 348
    },
    {
      "heading": "Grade Volumes 1",
      "text": "modulation modulation + xyloglobin + xylogeny +7-10: xylcholocoma xylcholocoma +ylocomastia +yrogenous +ymoglobinosis +yxylocoagulation +yrh +ymiformation +y.",
      "start_page": 349,
      "end_page": 350
    },
    {
      "heading": "- PCV:",
      "text": "CCNU (lomustine) 90 (cycle 1) - 110 (dosed dosed 2) mg/1. 1.4mg/m2, (max 2mg) IV d8+regimens regimens (15 15 sessions) (18) PCV (as above) administered administered earlier",
      "start_page": 351,
      "end_page": 352
    },
    {
      "heading": "ASTROCYTOMA IDH – 3 3 (anaplastic anaplastic astrocytoma)",
      "text": "Temozolomide Temozolomide (75mg/m2/CPR CPR 2Gy/5 5 days/week for 6- 60 60 Gy) add add benefit(24). After CMR administration",
      "start_page": 352,
      "end_page": 352
    },
    {
      "heading": "ASTROCYTOMA IDH – grade grade 4",
      "text": "IDH IDH – with with CDKN2A/below below (bleed).",
      "start_page": 352,
      "end_page": 352
    },
    {
      "heading": "LANGUAGE IDH – grade grade 4",
      "text": "primary primary (IDH wild dose) gluotide gluotide and/time time (nilmodide + lythromide + 5 lylomodide). gluosomodide gluosomodide / behaviours behaviours (antic markers). therapy therapy (in MGMT) the the PET/CT brain (34) (36) (37) mutations mutations ( __MEDTERM6_/ __MEDterm7_, __MEDDERM8_/_MEDmaxTERM9_) (6) (8) and NTRK (larotrectininb, __MESTERM10_) (53) (54). 4 4 group:",
      "start_page": 352,
      "end_page": 355
    },
    {
      "heading": "75 75 mg/m d1",
      "text": "mg mg /2 2 mg) 70-75 70-75 mg/1000 1000 mg/retention retention (organ preservation strategies). Stages III, IV). Immunotherapy Immunotherapy (_MED7M)",
      "start_page": 355,
      "end_page": 364
    },
    {
      "heading": "1. PF+ pembrolizumab:",
      "text": "(CPS CPS expression1) 100 100 mg/1000 1000 mg/ infusion infusion (24 24 months).",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "2. Pembrolizumab:",
      "text": "(CPS CPS expression1) days days (24 24 months).",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "3. PF + Cetuximab [EXTREME format]:",
      "text": "(CPS CPS expression1) Cisplatin 100 mg/1000 1000 mg/ 15 15 (IV 400 mg/250 250 mg/dm2 each (not not accepted)",
      "start_page": 364,
      "end_page": 364
    },
    {
      "heading": "4. TPEX (EXTREME EXTREME scheme)",
      "text": "Docetaxel 75mg/75 75 mg/15 15 (IV 400 mg/ and and following",
      "start_page": 364,
      "end_page": 365
    },
    {
      "heading": "5. TP",
      "text": "IVplatin 75 mg/mg mg /750 750 mg/175 175 mg/1000 1000 mg/injection__MEDTERM0_400 injection__MEDTERM0_400 mg/t IV (following)",
      "start_page": 365,
      "end_page": 365
    },
    {
      "heading": "PD-L1 PD-L1 expression",
      "text": "1 1 Line) TPS TPS expression50%",
      "start_page": 366,
      "end_page": 366
    },
    {
      "heading": "75 75 mg/m2, IV",
      "text": "40 40 mg/IV IV (Docetaxel Docetaxel 75mg/__MEDTERM0_400 __MEDTERM0_400 mg/ m IV (charge), __MEDterm0_250 __MEDterm0_250 mg/__MEDTEM0_500 __MEDTEM0_500 mg/and and Cisplatin/continues continues 4: __MEDDERM5_. __MEDDERM5_.",
      "start_page": 366,
      "end_page": 367
    },
    {
      "heading": "expression expression 50%. PDL-1. PDL-1.",
      "text": "quinopreceptorase quinopreceptorase (prophylaxis) reaction reaction (pharmyxydrosis) with Cismplatin+Cycorticin+g. g.: Cisplatin/syndrome syndrome (dissociative tumor syndrome) the the Head/T1 T1 (> 1 cm) τοαι τοαι . mediated_MEDTERM32_, mediated_MEDTERM32_, [49-51]. tested. tested.",
      "start_page": 367,
      "end_page": 379
    },
    {
      "heading": "KARKINOS KARKINOS Thyreoidides",
      "text": "infarction infarction (the the +_MEX-Cyclobin+R_Cytrobin+Cydrosis=Cythrokine_Ctydrosis+__MEDDERM25_ __MEDDERM25_ (twice twice daily) and __MEDterm26_ (2 mg daily) 10 10 mg/radiotherapy radiotherapy [85] tested. tested.",
      "start_page": 380,
      "end_page": 384
    },
    {
      "heading": "III) DIAGNOSTIC APPROACH",
      "text": "ventricles ventricles (CTs or MRIs). with with PET/of of PET/ clinical clinical ‘scenarios' the the investigation",
      "start_page": 390,
      "end_page": 390
    },
    {
      "heading": "IV) CONFERENCE",
      "text": "Ca. Ca.",
      "start_page": 391,
      "end_page": 394
    },
    {
      "heading": "neoplasms neoplasms (G3).",
      "text": "ventricles ventricles (CT/MRI) Etoposide. Etoposide.",
      "start_page": 394,
      "end_page": 394
    },
    {
      "heading": "schema schema CAPE",
      "text": ". 1) IV IV + Paclitaxel 175mg/d1 d1 (Q21) cycles cycles 2) IV IV + Docetaxel 75mg/ m ,IV, d1) 394 394 3) Cispla 4) Oxalip 1200mg 7b) Therapeutics Therapeutics (FGFR, FGFR, NTRK) approach approach (\"two-step\") (Cyrhythmic companency_complexity syndrome) tool tool (VES-13, G8 etc) as as \"Sensable\" (fit) therapy therapy (standard of care). CHMEITHERAPE CHMEITHERAPE (Heraclitus Heraclitus Grade>2 (1,000 neutrophils/mm ). status status (PS>2) Note 1: radix, radix, neutrino(0)14 14 days), CAV CAV (ACO) SUPPLEMENTS SUPPLEMENTS (DOSE INTENSIT DEVIDANCE) OF OF LIBRATORS/OF OF PHILAGROSTIM/Lenograstim (G). 95% chemokinotherapy [II, B] and Hb10g/thinners thinners [circumvented iron/asymptomatics] baseline baseline [c. c./asymptigated asymptigated (CIb8g/1314 1314 g/dl [I,A]. Hb Hb 77-8g/ d/Inst Inst 1999;91:in in cancer: Rev Rev 2000;26:loss loss , disease disease (phosphoric phosphoric acid_inflation) . fractures fractures (I,A). fracture fracture (Fr.A). metastases metastases (I, B).thrombocytosis thrombocytosis (PMC) with with PMP-25% Thrombocytopenia (platelets 20,000/mcL) dysfunction dysfunction (uremia, drugs, MDS) (ASCO) coagulant coagulant (HITIT)",
      "start_page": 394,
      "end_page": 425
    },
    {
      "heading": "Patient characteristic Risk",
      "text": "risk risk (stomach, pancreas) risk risk (testicular, testicular, renal) 000 000 /10 10 g/of of erythropoies",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "0. 0.8% 0.3%",
      "text": "1. 1.8% 2%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "7. 7.1% 6.7%",
      "text": "VTE VTE > 1500 mg/m2 mg/ Methotrexate Methotrexate >50 mg/ 250 mg/M2 g/m2, mg/mm2 /m2 – >Nab-pa Nab-pa mg/m2 m2 g",
      "start_page": 425,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "mg mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "300 300 mg/0.5 mg",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO?",
      "text": "01 01 mg/kg IV; 1 transdermal patch; 10 mg",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "8 mg ; 8 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "mg mg ; mg mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "100 mg once",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO",
      "text": "5 mg ; 5 mg IV",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "PO or",
      "text": "2 2 and",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "(daily daily on",
      "text": "daily daily on",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "(30 to 90%)",
      "text": "(10 to 30%) 4. 4.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "IV IV (days days 2",
      "text": "3. 3.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "IV IV (8 mg per",
      "text": "we we use",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "5-HT3 antagonist (the the following):",
      "text": "μ (mu) action. action.Naloxegulor:constipation constipation (opiaid-induced syndrome, OIC) program, program, [10-11] NACASY NACASY [12] and other studies",
      "start_page": 432,
      "end_page": 433
    },
    {
      "heading": "1. Opioids.",
      "text": "mg mg (aspirin-adreceptor) the the day-mg. mg.",
      "start_page": 435,
      "end_page": 438
    },
    {
      "heading": "Pain Pain (BTcP)",
      "text": "pain pain (BTcP) with with (Abstral); synaptic synaptic receptors; of of serotonin; the the riboflavin; the the ribocannabinoid; ribopinoid ribopinoid gland; fentanylanyl fentanylanyl (PecFent), mucosa. mucosa. , fundamentals fundamentals (2015 Jun; 56(6): Buprenorphine Buprenorphine – economics economics journal",
      "start_page": 438,
      "end_page": 447
    },
    {
      "heading": "Grade 1 Mild:",
      "text": "Rash covering 10% symptoms symptoms (itching, itching, feeling",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "Grade 2 Moderate:",
      "text": "Rash covering 10-30% symptoms symptoms (covering covering >30% mild mild symptomatology",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "Grade 3 Serious:",
      "text": "Abnormality covering >30% grade grade 4; life-threatening reactions (corticosteroids corticosteroids (0. 0.05%, triamcinolone 0.1% phynphodynx phynphodynx -phyngoics phyngoics - phynmocytosis phynmocytosis - Ozarotyne 0.05% of immunotherapy - UVB narcodontism - or or - 1025 1025 mg/ week psoriasis - bid bid - anti-TNFa (_MEDTERM3_,_MEDterm4___) health health professionals: 16 16 (DE DE (2019). Monogr Monogr 53:lg009, doi: Res. Res. 2021; 4: al al (2021). Jaw Jaw (MRONJ). Medicina 57:assistor assistor (2020ve) fusion fusion – __MESTERM16__Trfusion __MESTERM16__Trfusion gene",
      "start_page": 449,
      "end_page": 467
    },
    {
      "heading": "day, day, continuously",
      "text": "TMB (10 10 mut/Mb), CDx_assay CDx_assay (valid valid platforms) 21 21 days",
      "start_page": 467,
      "end_page": 468
    },
    {
      "heading": "Gene Fusion NTRK",
      "text": "Tarotrectinib – C49 (genes genes __MEDETR1_) 00 00 mg/25 25 mg/Organization Organization (WHO, 2014) as \"artis artis Mild-moderate: GFR 30-89ml/min - Dependable! Competitors Competitors 5HT3: Antagonists Antagonists NK1: aprepitant , fosaprepitant Corticosteroids: receptor receptor antagonists: Elassona Elassona sedatives:",
      "start_page": 468,
      "end_page": 480
    },
    {
      "heading": "Confrontation",
      "text": "obstruction obstruction (Levomeprom Levomeprom - atet atet (send nnabis). P. P., Palliative Palliative Medicinen/California. California. I'syndrome. syndrome. I'if if you'that that it'disease. disease. It'efficacious efficacious (in the immunodeficiency) b. b. o'as as ECDC'occia occia . sputum. sputum.",
      "start_page": 480,
      "end_page": 504
    },
    {
      "heading": "HiB/ Influenza Hemophilus vaccination",
      "text": "disease disease [55]. cause cause insignia",
      "start_page": 505,
      "end_page": 507
    },
    {
      "heading": "HPV/Human papillomavirus",
      "text": "population. population.",
      "start_page": 507,
      "end_page": 507
    },
    {
      "heading": "HZV/ Herpes shingles vaccine",
      "text": "Emphasis zos. , . patient patient [2, 2,36) noun noun (1, 1, 19). way, way, we'work. work. We'SAB SAB [74], if if it'million. million.",
      "start_page": 509,
      "end_page": 512
    },
    {
      "heading": "tida tida (respiratory syncytialvirus, RSV) is",
      "text": "verse verse [81] the the plague; the the sacrum; Oncology Oncology (ASCO) for for a), mi mi let'in in iyron",
      "start_page": 513,
      "end_page": 519
    },
    {
      "heading": "added, added,> (from previous page)",
      "text": "Row 1:\nMolecules Molecules (corresponding) RowRow 2:\nexpression expression (ER), receptor receptor (PR) RowRow 3:\nor or overexpression",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "or or EC>",
      "text": "Row 1:\nHER2-positive (non luminal)RowRow 2:\n‘Basal-like’HER2. HER2.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "or or EC>",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\ntumors tumors and/RowRow 4:\nLuminal b-like",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "or or EC> (column 1)",
      "text": "Row 1:\nHER2-positive (non luminal)Row 2:\n‘Basal-like’",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "or or EC> (column 1)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRaw Raw 4: RowRow 5:\nHER2- positive (non luminal)Row 6:\n‘Basal-like’",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Oncol Oncol 2001; 19:3103.> (from previous page)",
      "text": "Row 1:\nMed. Med. 2016; 375(18): 1738-1748Row 2:\n Row 3:\ncarboplatin carboplatin and/RowRow 4:\nneoadjuvant once-per-week piclitaxel",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "heading heading Etotoside/Cisplatin>",
      "text": "Row 1:\nVinorelbine/Cisplatin Vinorebine25mg/RowRow 2:\nCisplatin Gemcitabine/CusplatIN Gemcitabine80 mg/ m2 1250 mg/ Q21d Q21d Docetex/Row 3:\nCisplatelin",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "heading heading Etotoside/Cisplatin>",
      "text": "Row 1:\nEtoposide/Cisplatin Etotoside100 mg/ D1, D1,",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "heading heading Etotoside/Cisplatin> (column 2)",
      "text": "Row 1:\n25mg/RowRow 2:\n80 mg/m2, 1250 mg/ RowRow 3:\n75/mg/ m2, 75 mg/ M2Q21d; D1, q-21d D1;Row 4:\n75 mg / m2 500 mg/",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "heading heading Etotoside/Cisplatin> (column 2)",
      "text": "Row 1:\n100 mg/ D1, D1,",
      "start_page": 87,
      "end_page": 87
    },
    {
      "heading": "heading heading Etoposide/Cisplatin> (from previous page)",
      "text": "Row 1:\nDocetaxel/Carboplatin Docetaxel75 mg/ RowRow 2:\nCarbopatin Paclitaxel/6 6 200mg/RowRow 3:\nCarboplatelin Pemetrexed/Carbotlatin",
      "start_page": 88,
      "end_page": 88
    },
    {
      "heading": "Index Index (PS) 2>",
      "text": "Row 1:\nDocetaxel/Gemcitamine Docetaxel100 mg/ RowRow 2:\nGemcitabine Paclitaxel/mg mg / m2 200mg/RowRow 3:\nGemcitabite Paclitabine",
      "start_page": 89,
      "end_page": 89
    },
    {
      "heading": "heading heading AVAiL>",
      "text": "Row 1:\nRowRow 2:\nPaclitaxel Carboplatin __MEDreM0_200mg/1 1 15mg/kgDay 1;q21d Day 1;Q21d day: AVAiLRow 4:\nCisplatin Gemcitabine__MEDTERM0",
      "start_page": 92,
      "end_page": 92
    },
    {
      "heading": "CHEMETHERAPY CHEMETHERAPY MAINTENANCE> (from previous page)",
      "text": "Row 1:\nPemetrexed500 mg/RowRow 2:\n__MEDTERM0_150 mg/with with platinum",
      "start_page": 94,
      "end_page": 94
    },
    {
      "heading": "CHEMETHERAPY CHEMETHERAPY MAINTENANCE> (from previous page)",
      "text": "Row 1:\n__MEDTERM0_150 mg/non-Row non-Row 2:\n__MEDterm1_250 mg/non-Row non-Row 3:\n_MEDTERm2_40 mg/Dayaccepted toxicity",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "CHEMETHERAPY CHEMETHERAPY MAINTENANCE> (column column 2)",
      "text": "Row 1:\nErlotinibRow 2:\n__MEDterm1__Row 3:\n__MEDTERm2___Row 4:\n__MESTERM3__WOW 5: __MEDERM4__ WOW 6: M6__-WOW M6__-WOW 7: ___MEPERM0 _MEMERM8__",
      "start_page": 106,
      "end_page": 106
    },
    {
      "heading": "heading heading C64>",
      "text": "Row 1:\n Row 2:\nSloan Sloan - RowRow 3:\nRowRow 4:\nRaw Raw 5: row row 6: (more more criteria)",
      "start_page": 263,
      "end_page": 263
    },
    {
      "heading": "heading heading C64> (from previous page)",
      "text": "Row 1:\n Row 2:\nConsortium Consortium (Heng Criteria)Row 3:\nRowRow 4:\nRaw Raw 5: row row 6:",
      "start_page": 264,
      "end_page": 264
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (from previous page)",
      "text": "Row 1:\nOncol Oncol 2014; 7:628Row 2:\ncarcinoma carcinoma of",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 1)",
      "text": "Row 1:\nHarbRow 2:\nRowRow 3:\nRowRow 4:\nRowRow 5:\ntreatRow 6:\nRowRow 7:\nplusRow 8:\nRowRow 9:\nunnnRow 10:\nRowRow 11:\ncarcRow 12:\nRowRow 13:\ncomRow 14:\nconcRow 16:\ncanc Row Row: 15:",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 2)",
      "text": "Row 1:\nCase Case Rep: Oncol 2014; 7:628Row 2:\nprimary primary carcinoma:",
      "start_page": 399,
      "end_page": 399
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (from previous page)",
      "text": "Row 1:\n Row 2:\nal. al. Paclitaxel/carboplatin/RowRow 3:\ngemcitabine/primary primary site: a",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (from previous page)",
      "text": "Row 1:\nCancer Cancer 1987; 59:572.Row 2:\nRowRow 3:\nOnc. Onc. 2010:Oncol Oncol 2000; 18:311.Row 20:\nRowRow 21:\nTomography/Detecting Detecting Gastro-Entero-Pancreatic Neurodecritic Tum",
      "start_page": 400,
      "end_page": 400
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (from previous page)",
      "text": "9Row 2:\nRowRow 3:\nImaging Imaging 2010; no no A:S83Row 4:\nDS, Klimstra",
      "start_page": 401,
      "end_page": 401
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (from previous page)",
      "text": "Row 1:\nRowRow 2:\nLiving Living (ADL) Live Live (IADL)Row 3:\nAccompanying Diseases‘and and Go' Index Index (CSI)Row 4:\nRating Rating ScaleGtric",
      "start_page": 403,
      "end_page": 403
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (from previous page)",
      "text": "Row 1:\nRowRow 2:\nGroup 1: \"Capacity\" (\"fit\")patients patients 3: Group 2: \"Vulnerable\" ('Vulneable')ADL ADL dependence",
      "start_page": 404,
      "end_page": 404
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (from previous page)",
      "text": "Row 1:\nO. O., >20%Row 3:\n Row 4:\nCancer bladder Cyst(dd)MVAC (doxorubicin, cisplatin)Row 5:\nBreast cancer",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 1)",
      "text": "20Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\nRowRow 5:\nRaw 6: row 7: row 8: ·Row 9:\nRowRow 10:\n?",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 2)",
      "text": "Forty-four:Row 42:\n Row 40:\n Row 45:\n Row 41:\n Row 34:\n Row 26:\n Row 21:\n Row 22:\n Row 23:\n Row 19:\n Row 18:\n Row 20:\n Row 27:\n Row 24:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 11:\n Row 25:\n Row 31:\n Row 12:\n Row 28:\n Row 29:\n Row 32:\n Row 8:\n Row 10:\n Row 9:\nRow 2",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 3)",
      "text": "Forty-four: 40 Row: 48 Row: 42 Row: 41 Row: 34 Row: 4 Row: 1 Row: 3 Row: 5 Row: 8:Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 21:\n Row 22:\n Row 23:\n Row 24:\nRow",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 4)",
      "text": "Forty-four: Row forty-nine: forty forty one: Row three: Row four: Row six: Row seven: Row eight: Row nine: Row ten:Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 21:\n Row 22:\n Row 23:\n Row 24:\nRow",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 5)",
      "text": "Forty-four:Row 1:\nheapsRow 2:\n Row 3:\n Row 4:\n Row 5:\nsRow 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 19:\n Row 21:\n Row 22:\n Row 23:\n Row 24:\nRow",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 6)",
      "text": "48Row 1:\niotherRow 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 17:\n Row 18:\n Row 19:\n Row 21:\n Row 22:\n Row 23:\n Row 24:\nRow",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 7)",
      "text": "48Row 1:\nrapsRow 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 21:\n Row 22:\n Row 23:\n Row 24:\nRow",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 8)",
      "text": "Row 1:\nO. O. >20%Row 2:\n Row 3:\n(dd)MVAC (d d cisplatin)Row 5:\nTAC (RowRow 6:\nRaw",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 9)",
      "text": "37Row 1:\n%Row 2:\n Row 3:\n Row 4:\ndoxoruRow 5:\nphamiRow 6:\n Row 7:\nhosphaRow 8:\n Row 9:\n Row 10:\nab)Row 11:\n Row 12:\nycin,Row 13:\n Row 14:\nnomycRow 15:\nfamideRow 16:\n Row 17:\n Row 18:\nmy,Row 20:\n Row 19:\nRow",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 10)",
      "text": "Row 27:\n Row 26:\n Row 29:\n Row 23:\n Row 34:\n Row 21:\n Row 22:\n Row 31:\n Row 19:\n Row 13:\n Row 14:\ncin,Row 15:\nRowRow 16:\n Row 17:\n Row 18:\n Row 20:\n Row 10:\n Row 11:\n Row 12:\n Row 24:\n Row 28:\n Row 25:\n Row 32:\n Row 38:\n Row 35:\n Row 39:\n Row 37:\n Row 40:\n Row 8:\n Row 7:\n Row 9:\nRow 2",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 11)",
      "text": "Row 27:\n Row 29:\n Row 26:\n Row 23:\n Row 31:\n Row 34:\n Row 21:\n Row 22:\n Row 19:\n Row 13:\n Row 14:\n Row 16:\n Row 17:\n Row 18:\n Row 20:\n Row 24:\n Row 25:\n Row 11:\n Row 28:\n Row 12:\n Row 10:\n Row 15:\n Row 8:\n Row 7:\n Row 32:\n Row 9:\n Row 3:\n Row 4:\n Row 6:\nRow 2",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 12)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\n Row 17:\n Row 18:\n Row 19:\n Row 20:\n Row 21:\n Row 22:\n Row 23:\n Row 24:",
      "start_page": 409,
      "end_page": 409
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (from previous page)",
      "text": "Row 1:\n Row 2:\n Row 3:\nDT-PACE (RowRow 4:\netoposide etoposide ) bortezomib (VTD-Pace)Row 5:\nlung lung cancer",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 1)",
      "text": "Row 1:\n Row 2:\nRaw 3: DT-PACE (RowRow 4:\nborezomib borezomib (VTD-Pace)Row 5:\ncancerDP cancerDP (docetaxel, carplatin)",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\nomide,Row 4:\nhamide, etoposide )Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\nmide, etoposide)Row 10:\n Row 11:\nicin, etoposide) Raw 12:Row 13:\natin)Row 14:\nin)",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "SCHEMES SCHEMES CAPE> (column column 3)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:\n Row 10:",
      "start_page": 410,
      "end_page": 410
    },
    {
      "heading": "7. 7.1% 6.7%>",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\nrisk risk (stomach, pancreas)2Row 5:\nHigh risk (testicular, preliminary)1Row 6:\nPre-chemotherapeutic pellet",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "7. 7.1% 6.7%>",
      "text": "Row 1:\nRowRow 2:\n Row 3:\n0Low0.8%0.3%Row 4:\n1,2Intermediate1.8%2%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "7. 7.1% 6.7%> (column 1)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\nrisk risk (stomach, pancreas)Row 5:\nHigh risk (testicular, renal)Row 6:\n000 000 / lymphomic Haemolytic",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "7. 7.1% 6.7%> (column 1)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\n0Low0.8%Row 4:\n1,2Intermediate1.8%",
      "start_page": 425,
      "end_page": 425
    },
    {
      "heading": "7. 7.1% 6.7%> (from previous page)",
      "text": "Row 1:\nRhubarboxicinate Rhubarboxicinate Rw: HighAnthraclinine/cyclophosphamide combinationStreptozotocinEpirubicin >90 mg/m2, Doxorubicins60mg/m2Row 3:\nSplatinDakarbazineIphosphamamideW2Rw 4:",
      "start_page": 428,
      "end_page": 428
    },
    {
      "heading": "7. 7.1% 6.7%> (from previous page)",
      "text": "Row 1:\nRowRow 2:\nPanitumabPertuzumabe",
      "start_page": 429,
      "end_page": 429
    },
    {
      "heading": "7. 7.1% 6.7%> (column column 1)",
      "text": "Row 1:\nRowRow 2:\nPanitumumabPertuzumab",
      "start_page": 429,
      "end_page": 429
    },
    {
      "heading": "heading heading (daily daily at>",
      "text": "W.R.: R.W.: W.D.: W.O.W; W.C.: 30 Row: Wr.: Raw: Wrew: Wrow/Wrought: Wraw: WOW: Wrestling: Warrow: Wrack: Wrow: Wow: Wtw: www:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at>",
      "text": "Row 1:\nRowRow 2:\nvomitingRow 3:\n(>90%)",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at>",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n Row 4:\nRowRow 5:\nRowRow 6:\nunpretentious/ fosaprepitant/",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at> (column 1)",
      "text": "Row 1:\n Row 2:\nKiRow 3:\nRaw 4: row 5: Increase vomiting>90%IncreasedRow 6:\nindirectRow 7:\n(>90%Row 8:\n)",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at> (column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\ndangerRow 4:\n Row 5:\n Row 6:\n Row 7:\nRowRow 8:\nsRow 9:\n%)Row 10:\n Row 11:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at> (column 3)",
      "text": "Row 1:\n Row 2:\n Row 3:\nRowRow 4:\n Row 5:\n Row 6:\n Row 7:\nDangerRow 8:\n Row 9:\n Row 10:\n Row 11:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at> (column 4)",
      "text": "Row 1:\n Row 2:\n Row 3:\nyouRow 4:\n Row 5:\n Row 6:\n Row 7:\nnosRow 8:\n Row 9:\n Row 10:\n Row 11:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at> (column 5)",
      "text": "40Row 1:\n Row 2:\nPharmaRow 3:\nRaw 4: row 5: RowRow 6:\nrow 7: raw 8: ?",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at> (column 6)",
      "text": "45Row 1:\n Row 2:\n Row 3:\nacoonRow 4:\n Row 5:\n Row 6:\n Row 7:\nTagRow 8:\n Row 9:\n Row 10:\n Row 11:\n Row 12:\n Row 13:\n Row 14:\n Row 15:\n Row 16:\nIttyRow 17:\n Row 18:\n Row 19:\n Row 21:\n Row 22:\n Row 23:\nRow",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at> (column 7)",
      "text": "140 140 mg: 420 420 mg; w w 4w: Row 4 WOW: 450 450 mg: Row 3Way:Row 12:\n Row 4:\nWreck (RowRow 7:\nRow 9 : Raw Raw 10:Row 11:\n Row 13:\n Row 6:\n Row 8:\n Row 14:\nRow",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "heading heading (daily daily at> (column 8)",
      "text": "#$##=##/## Row:##.##&##;## Row :##40##Row:#42## Row:Row 1:\n Row 2:\nw: Raw: W.W.:W. Row:",
      "start_page": 430,
      "end_page": 430
    },
    {
      "heading": "competitor competitor (the the following):>",
      "text": "WOW: ROW: ROW : ROW = ROW = RW = RW = WOW = WROW = Row = Rw = WW = 30 RW : RW + RW x RW; RW: RW_RW: rw = rw= RWW = rW = ww = R.",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "competitor competitor (the the following):>",
      "text": "Row 1:\nRowRow 2:\n(30 to 90%)Row 3:\nno-carboplatin",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "competitor competitor (the the following):>",
      "text": "Row 1:\nPORow 2:\n Row 3:\nIV IV (when when using",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "competitor competitor (the the following):>",
      "text": "Row 1:\n Row 2:\ndays days 2",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "competitor competitor (the the following):>",
      "text": "Row 1:\nRowRow 2:\n(30 to 90%)Row 3:\nwith carboplatin",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "competitor competitor (the the following):>",
      "text": "Row 1:\nRowRow 2:\n(10 to 30%)",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "antagonist antagonist (the the following):> (column 1)",
      "text": "13:Row 2:\nRaw 3: Round 4: Medium risk (30 to 90%) RowRow 5:\n(30 to 90%):Row 6:\nNo-carbRow 7:\n·Row 8:\n«Row 9:\nMedium risk (90 90 percent) with carbohydratesMeterium",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "antagonist antagonist (the the following):> (column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\nRowRow 5:\n Row 6:\nOplatinianRow 7:\n Row 8:\n Row 9:\n Row 10:\nRowRow 11:\n Row 12:\natinRow 13:\n Row 14:\n Row 15:\n Row 16:\nHymnesisRow 17:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "antagonist antagonist (the the following):> (column 3)",
      "text": "4Row 1:\n Row 2:\nRaw 3: RowRow 4:\n Row 5:\nh5HT3 antagonist (the the following): row 6: row 8:",
      "start_page": 431,
      "end_page": 431
    },
    {
      "heading": "3 3 Serious:>",
      "text": "Row 1:\nGrade 1mild: Rash covering 10% symptoms symptoms (RowRow 2:\nGrade 2burning, pain) Moderate: Rash masking 10-30% symptoms symptoms (sensation, pain), covering covering >30% > mild mild symptoms",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "3 3 Serious:>",
      "text": "Row 1:\n Row 2:\nRowRow 3:\nwith with administration",
      "start_page": 449,
      "end_page": 449
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Row 1:\n Row 2:\nRowRow 3:\npressures pressures and",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\n(benzene benzene peroxide).",
      "start_page": 450,
      "end_page": 450
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Row 1:\nRowRow 2:\nAlopecia- cells. cells. - at at 65%",
      "start_page": 452,
      "end_page": 452
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "row 1: drugs. drugs. -palpitations palpitations (the the sinuses) - treatment. treatment. - row row 2: reversible. reversible. - Skin Skin findings: - necrosis necrosis (rarely) - trunk trunk - same. same.",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Row 1:",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "3 3 Serious:> (column column 4)",
      "text": "Row 1:\ndrugs. drugs. - rashes rashes - therapy therapy - RowRow 2:\n- reversible. reversible. - tissues. tissues. - 1 1 – 6%, children. children.",
      "start_page": 453,
      "end_page": 453
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Row 1:\n- sinuses sinuses - glands glands - palpitation palpitation - soles soles - 5-FU 5-FU - observed observed - nymuscus. nymuscus.",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Row 1:\ntreat treat Toxicity/ RowRow 2:\npustules, without",
      "start_page": 454,
      "end_page": 454
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Row 1:\nof of row: sinuses sinuses - sinuses sinuses (fluoric sinuses) - rash. rash. -tumors. tumors.- lesions lesions - Diathermy – RowRow 7:\nYBRpAodFe Rheumatitis- nodules nodules below-NSAFF",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "3 3 Serious:> (column column 4)",
      "text": "Row 1:\n- RowRow 2:\nrashes rashes - aromas aromas - RowRow 3:\nGrade 1 - antiseptics antiseptics (chlorin chlorin solution)",
      "start_page": 455,
      "end_page": 455
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Row 1:\nMKIs- Systemic corticoids (prednisoneRow 2:\nLCDeuKk4th/ 6 inhibitors - asymptomatic asymptomatic - 5-1 5-1 mg/rash rash - Monitoring - Local Corticoids - Cream pimecrolimus-tacrolims",
      "start_page": 456,
      "end_page": 456
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "Raw 1: Dermal Toxicity/ complexes_Fluoridal complexes_Fluoridal complexes=Rough complexes===Row 2:\n Row 3:\nCilidoblastous (RowRow 4:\nrashes Eczematic-type reactions=See C2 - exfoliation exfoliation -extremities extremities -RowRow 4:\n- unresponsive unresponsive (0.5-1 mg/kg/day prednisolone)Row 8:\nthe the mouth",
      "start_page": 457,
      "end_page": 457
    },
    {
      "heading": "3 3 Serious:> (column column 4)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\nSee C2 - exfoliation exfoliation - extremities extremities - RowRow 5:\npruritus - scale. scale. -scalp. scalp. - of of psoriasis",
      "start_page": 457,
      "end_page": 457
    },
    {
      "heading": "3 3 Serious:> (from previous page)",
      "text": "",
      "start_page": 458,
      "end_page": 458
    },
    {
      "heading": "fusion fusion NTRK> (from previous page)",
      "text": "Row 1:\nimpaired impaired - squeezing squeezing - rheumatosis rheumatosis - RowRow 2:\nMild-moderate: GER 30-89ml/min - Dependent",
      "start_page": 472,
      "end_page": 472
    },
    {
      "heading": "fusion fusion NTRK> (from previous page)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nRowRow 4:\nBecomeRow 5:\nHydromorphone(Yes)RowRow 6:\nOxycodoneYes",
      "start_page": 472,
      "end_page": 472
    },
    {
      "heading": "fusion fusion NTRK> (from previous page)",
      "text": "Row 1:\nlevel level 2: oxycodone1. oxycodone1.5:1StrongRow 3:\non on buprenorphineTTS75:1PatientRow 4:\nto to fentanylTTS=100:1Powerful",
      "start_page": 474,
      "end_page": 474
    },
    {
      "heading": "fusion fusion NTRK> (from previous page)",
      "text": "Row 1:\n Row 2:\nand and vomiting",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "fusion fusion NTRK> (from previous page)",
      "text": "Row 1:\n Row 2:\nRowRow 3:\nRowRow 4:\nPractical measures: RowRow 5:\nRowRow 6:\nRow",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "fusion fusion NTRK> (column column 1)",
      "text": "Row 1:\n Row 2:\nacute acute nautilus",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "fusion fusion NTRK> (column column 1)",
      "text": "Row 1:\n Row 2:\nRowRow 3:\nRowRow 4:\nPractical measures: RowRow 5:\nRowRow 6:\nRowRow 7:\nUsing each other's antimetics",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "fusion fusion NTRK> (column column 2)",
      "text": "Row 1:\n Row 2:\nja and vomiting",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "fusion fusion NTRK> (column column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\nRowRow 5:\n Row 6:\nRowRow 7:\n Row 8:\n Row 9:\nRangeRow 10:\n Row 11:\ntheRow 12:",
      "start_page": 478,
      "end_page": 478
    },
    {
      "heading": "fusion fusion NTRK> (from previous page)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nAntagonists 5HT3: RowRow 4:\nAntagonist NK1: RowRow 5:\nCorticosteroids: dexamethasoneRow 6:\nDopamine receptor antagonists: halomoid proproids,",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "fusion fusion NTRK> (column column 1)",
      "text": "Row 1:\nRowRow 2:\n Row 3:\nAntagonists 5HT3: RowRow 4:\nAntagonist NK1: RowRow 5:\nCorticosteroids: dexamethasoneRow 6:\nDopamine receptor antagonists: haloperid,",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "fusion fusion NTRK> (column column 2)",
      "text": "Row 1:\n Row 2:\n Row 3:\nnRow 4:\n Row 5:\n Row 6:\netiquette -metoclopr",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "fusion fusion NTRK> (column column 3)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\nramide",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "fusion fusion NTRK> (column column 4)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\ne, dom",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "fusion fusion NTRK> (column column 5)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\nmperid",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "fusion fusion NTRK> (column column 6)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\ndone",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "fusion fusion NTRK> (column column 7)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:",
      "start_page": 479,
      "end_page": 479
    },
    {
      "heading": "heading heading Face>",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nparaffin paraffin Macrogol",
      "start_page": 480,
      "end_page": 480
    },
    {
      "heading": "heading heading Face> (from previous page)",
      "text": "Row 1:\n Row 2:\nRowRow 3:\nSmith. Smith.",
      "start_page": 485,
      "end_page": 485
    },
    {
      "heading": "heading heading Face> (from previous page)",
      "text": "Row 1:\n Row 2:\nKroook Kroook JE; jk jk 3:",
      "start_page": 486,
      "end_page": 486
    },
    {
      "heading": "heading heading Face> (from previous page)",
      "text": "Row 1:\n Row 2:\nRowRow 3:\nGH, Oncology",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "heading heading Face> (from previous page)",
      "text": "Row 1:\nOncol. Oncol. 2014;32(17):RowRow 3:\nCancer-related Cancer-related fatigue: RowRow 4:\nStates States sample",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "heading heading Face> (from previous page)",
      "text": "Row 1:\n Row 2:\n Row 3:\n Row 4:\n Row 5:\n Row 6:\n Row 7:\n Row 8:\n Row 9:",
      "start_page": 488,
      "end_page": 488
    },
    {
      "heading": "heading heading Face> (from previous page)",
      "text": "Row 1:\nRowRow 2:\nDelirium Delirium (acute confusional states).JAMA. 1987;258(13):1789.Row 3:\nAmicustry Amicustry 1983:10",
      "start_page": 490,
      "end_page": 490
    },
    {
      "heading": "tida tida (antivirus, antivirus, RSV) is > (from previous page)",
      "text": "Row 1:\nlus. lus.",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "tidas tidas (antivirus, antivirus, RSV) is > (column column 4)",
      "text": "Row 1:\nRecommendationChronicsObservationsRow 2:\nstroke stroke os",
      "start_page": 517,
      "end_page": 517
    },
    {
      "heading": "tida tida (antivirus, antivirus, RSV) is > (from previous page)",
      "text": "Row 1:\nB B /wicked wicked man; his his wombs; her her womb; a a womb; her her mother's womb:",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "tidas tidas (antivirus, antivirus, RSV) is > (column column 6)",
      "text": "Row 1:\nmind mind (RowRow 2:\npass pass it) mental mental (habitation, use",
      "start_page": 518,
      "end_page": 518
    },
    {
      "heading": "tida tida (antivirus, antivirus, RSV) is > (from previous page)",
      "text": "Row 1:\nπο. πο. ..",
      "start_page": 519,
      "end_page": 519
    },
    {
      "heading": "tidas tidas (antivirus, antivirus, RSV) is > (column column 5)",
      "text": "Row 1:\nnos) RowRow 2:\nweakened mind, ‘live dos' RowRow 3:\n(to withdraw)",
      "start_page": 519,
      "end_page": 519
    }
  ]
}